ValueTrust Acts as Financial Advisor to the Management Board of Vita 34

Munich, Germany (4 June 2021)

Valuation Research Group (VRG), a leading global provider of independent valuation, advisory, and value-related services, is pleased to announce that VRG’s Germany-based member firm, ValueTrust acted as a financial advisor to the management board of Vita 34 on the proposed combination with PBKM.

On May 31 2021, Management Boards of Vita 34 AG (“Vita 34“), and Polski Bank Komórek Macierzystych S.A., Warsaw (“PBKM“) have entered into a business combination agreement under which Vita 34 agreed to offer to the shareholders of PBKM to exchange all shares of PBKM for shares in Vita 34 by way of a contribution in kind. Based on the 2020 reported results, the business combination would create a pan-European cord blood bank with combined revenues of approximately EUR 67 million and an aggregated market capitalization of approximately EUR 249 million.

In this context, ValueTrust provided a valuation opinion and determined the exchange ratio for shares in Vita 34 and PBKM.

About Vita 34
Vita 34 was founded in Leipzig in 1997 and is today one of the leading cell banks in Europe. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since been offering the collection logistics, processing and storage of stem cells from umbilical cord blood and umbilical cord tissue as a full-service provider for cryopreservation. More than 247,000 customers from more than 20 countries have already provided for the health of their families with a cell depot at Vita 34.

About PBKM
Polski Bank Komórek Macierzystych is the parent company of the international FamiCord Group (“FamiCord”), which operates stem cell banks in Europe. The core business of FamiCord is the procurement, processing and long-term storage of stem cells from umbilical cord blood and other post-fetal tissues on behalf of the parents (family banking). In addition, FamiCord invests in the development of services for the production of drugs for advanced therapy medicinal products, which are considered one of the most important developments in modern medicine. Since May 2016, PBKM has been listed in the main segment of the Warsaw Stock Exchange.

About VRG
Valuation Research Group (VRG) is a global valuation practice that furnishes expert and independent opinions of value for solvency, fairness, business enterprises, intangible assets, capital stock, equity interests, real estate and fixed assets. VRG has a network of over 1,300 professionals located in offices throughout continental Europe and the United Kingdom, Brazil, China, India, Mexico, Canada, Argentina, Australia, and the United States. The Germany-based practice operates as ValueTrust.